Elizabeth M. Swisher

ORCID: 0000-0003-2331-0434 · 11 papers in corpus
observational 2024
eLife ·doi:10.7554/elife.89830

Investigating the human fallopian tube (FT) microbiota has significant implications for understanding the pathogenesis of ovarian cancer (OC). In this large prospective study, we collected swabs intraoperatively from the FT and other surgic…

observational 2024
Gynecologic Oncology ·doi:10.1016/j.ygyno.2024.07.690

BACKGROUND: Individuals with germline BRCA1 and BRCA2 pathogenic variants (BRCA carriers) are at high risk of developing high grade serous ovarian carcinoma (HGSC). HGSC is predominantly driven by TP53 mutations, but mutations in this gene …

other 2022
Cancer research communications ·doi:10.1158/2767-9764.crc-22-0314

Current screening methods for ovarian cancer (OC) have failed to demonstrate a significant reduction in mortality. Uterine lavage combined with TP53 ultra-deep sequencing for the detection of disseminated OC cells has emerged as a promising…

lab-animal 2021
Molecular cancer therapeutics ·doi:10.1158/1535-7163.mct-20-0809

Ovarian clear cell carcinoma (OCCC) is a rare, chemo-resistant subtype of ovarian cancer. To identify novel therapeutic targets and combination therapies for OCCC, we subjected a set of patient-derived ovarian cancer cell lines to arrayed h…

observational 2020
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists ·doi:10.1097/pgp.0000000000000604

Intraepithelial fallopian tube neoplasia is thought to be a precursor lesion to high-grade serous carcinoma of the Müllerian adnexae, particularly in women with BRCA1 or BRCA2 mutations. This association has led to recommendations to assess…

other 2020
Gynecologic Oncology ·doi:10.1016/j.ygyno.2019.11.124

OBJECTIVE: Pap tests hold promise as a molecular diagnostic for serous ovarian cancer, but previous studies reported limited sensitivity. Furthermore, the presence of somatic mutations in normal tissue is increasingly recognized as a challe…

other 2015
Nucleic acids research ·doi:10.1093/nar/gkv111

To determine early somatic changes in high-grade serous ovarian cancer (HGSOC), we performed whole genome sequencing on a rare collection of 16 low stage HGSOCs. The majority showed extensive structural alterations (one had an ultramutated …

other 2013
Gynecologic Oncology ·doi:10.1016/j.ygyno.2013.05.028

OBJECTIVES: To develop an assay for anti-HE4 antibodies and assess such antibodies in sera from women with increased epidemiologic risk for ovarian cancer (infertility) and patients with ovarian cancer in comparison to controls. METHODS: A…

diagnostic-accuracy 2010
Cancer letters ·doi:10.1016/j.canlet.2010.03.013

The HE4 protein is overexpressed in ovarian carcinomas and can be detected in serum by an ELISA with sensitivity similar to CA125 and higher specificity for malignant disease. We now demonstrate that HE4 can also be detected in the urine at…

other 2010
Cancer ·doi:10.1002/cncr.25439

BACKGROUND: BRCA1 or BRCA2 (BRCA1/2)-mutated ovarian carcinomas may originate in the fallopian tube. The authors of this report investigated alterations in BRCA1/2 tubal epithelium to define the molecular pathogenesis of these carcinomas. …

observational 2008
Gynecologic Oncology ·doi:10.1016/j.ygyno.2008.07.036

OBJECTIVES: To define patterns of aberrant DNA methylation, p53 mutation and Her-2/neu overexpression in tissues from benign (n=29), malignant (n=100), and border line malignant ovaries (n=10), as compared to normal (n=68) ovarian tissues. …